Xie Y, Liu F, Wu Y, Zhu Y, Jiang Y, Wu Q
Mol Cancer. 2025; 24(1):51.
PMID: 39994787
PMC: 11849313.
DOI: 10.1186/s12943-025-02243-8.
Yu D, Zheng S, Sui L, Xi Y, He T, Liu Z
Front Immunol. 2024; 15:1466440.
PMID: 39600708
PMC: 11588630.
DOI: 10.3389/fimmu.2024.1466440.
Xu D, Tate M
Viruses. 2024; 16(10).
PMID: 39459869
PMC: 11512208.
DOI: 10.3390/v16101535.
Xu C, Jing W, Liu C, Yuan B, Zhang X, Liu L
Front Immunol. 2024; 15:1343325.
PMID: 39450183
PMC: 11499118.
DOI: 10.3389/fimmu.2024.1343325.
Coll R, Schroder K
Nat Rev Immunol. 2024; 25(1):22-41.
PMID: 39251813
DOI: 10.1038/s41577-024-01075-9.
Targeting NLRP3 Inflammasomes: A Trojan Horse Strategy for Intervention in Neurological Disorders.
Bayat Tork M, Fotouhi S, Roozi P, Negah S
Mol Neurobiol. 2024; 62(2):1840-1881.
PMID: 39042218
DOI: 10.1007/s12035-024-04359-2.
MNDA, a PYHIN factor involved in transcriptional regulation and apoptosis control in leukocytes.
Bottardi S, Layne T, Ramon A, Quansah N, Wurtele H, Affar E
Front Immunol. 2024; 15:1395035.
PMID: 38680493
PMC: 11045911.
DOI: 10.3389/fimmu.2024.1395035.
Identification and characterization of endogenous retroviruses upon SARS-CoV-2 infection.
Guo X, Zhao Y, You F
Front Immunol. 2024; 15:1294020.
PMID: 38646531
PMC: 11026653.
DOI: 10.3389/fimmu.2024.1294020.
New Insights on NLRP3 Inflammasome: Mechanisms of Activation, Inhibition, and Epigenetic Regulation.
Kodi T, Sankhe R, Gopinathan A, Nandakumar K, Kishore A
J Neuroimmune Pharmacol. 2024; 19(1):7.
PMID: 38421496
PMC: 10904444.
DOI: 10.1007/s11481-024-10101-5.
Design principles for inflammasome inhibition by pyrin-only-proteins.
Wu S, Garg A, Mazanek Z, Belotte G, Zhou J, Stallings C
Elife. 2024; 13.
PMID: 38252125
PMC: 10803020.
DOI: 10.7554/eLife.81918.
The role of inflammasomes in human diseases and their potential as therapeutic targets.
Yao J, Sterling K, Wang Z, Zhang Y, Song W
Signal Transduct Target Ther. 2024; 9(1):10.
PMID: 38177104
PMC: 10766654.
DOI: 10.1038/s41392-023-01687-y.
Accelerated NLRP3 inflammasome-inhibitory peptide design using a recurrent neural network model and molecular dynamics simulations.
Ahmad B, Achek A, Farooq M, Choi S
Comput Struct Biotechnol J. 2023; 21:4825-4835.
PMID: 37854633
PMC: 10579963.
DOI: 10.1016/j.csbj.2023.09.038.
Methods to Measure NLR Oligomerization I: Size Exclusion Chromatography, Co-immunoprecipitation, and Cross-Linking.
Khare S, Devi S, Radian A, Dorfleutner A, Stehlik C
Methods Mol Biol. 2023; 2696:55-71.
PMID: 37578715
PMC: 11073631.
DOI: 10.1007/978-1-0716-3350-2_4.
Race between virus and inflammasomes: inhibition or escape, intervention and therapy.
Wu N, Zheng C, Xu J, Ma S, Jia H, Yan M
Front Cell Infect Microbiol. 2023; 13:1173505.
PMID: 37465759
PMC: 10351387.
DOI: 10.3389/fcimb.2023.1173505.
Inflammasomes: Mechanisms of Action and Involvement in Human Diseases.
Bulte D, Rigamonti C, Romano A, Mortellaro A
Cells. 2023; 12(13).
PMID: 37443800
PMC: 10340308.
DOI: 10.3390/cells12131766.
The NLRP3 inflammasome in viral infection (Review).
Zheng Q, Hua C, Liang Q, Cheng H
Mol Med Rep. 2023; 28(3).
PMID: 37417336
PMC: 10407610.
DOI: 10.3892/mmr.2023.13047.
Uncoupled pyroptosis and IL-1β secretion downstream of inflammasome signaling.
Li Y, Jiang Q
Front Immunol. 2023; 14:1128358.
PMID: 37090724
PMC: 10117957.
DOI: 10.3389/fimmu.2023.1128358.
CARD-only proteins regulate in vivo inflammasome responses and ameliorate gout.
Devi S, Indramohan M, Jager E, Carriere J, Chu L, de Almeida L
Cell Rep. 2023; 42(3):112265.
PMID: 36930645
PMC: 10151391.
DOI: 10.1016/j.celrep.2023.112265.
POP1 inhibits MSU-induced inflammasome activation and ameliorates gout.
de Almeida L, Devi S, Indramohan M, Huang Q, Ratsimandresy R, Pope R
Front Immunol. 2022; 13:912069.
PMID: 36225929
PMC: 9550078.
DOI: 10.3389/fimmu.2022.912069.
Inflammasome activation: from molecular mechanisms to autoinflammation.
Lara-Reyna S, Caseley E, Topping J, Rodrigues F, Jimenez Macias J, Lawler S
Clin Transl Immunology. 2022; 11(7):e1404.
PMID: 35832835
PMC: 9262628.
DOI: 10.1002/cti2.1404.